Jade Biosciences (JBIO) Equity Average (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of Equity Average data on file, last reported at $314.5 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 582.68% year-over-year to $314.5 million; the trailing twelve-month figure through Mar 2026 stood at $314.5 million (up 582.68% YoY), and the FY2025 full-year result was $142.9 million, up 356.0% from the prior year.
• Equity Average for Q1 2026 stood at $314.5 million, up from $255.9 million in the prior quarter.
• Across five years, Equity Average topped out at $314.5 million in Q1 2026 and bottomed at -$65.2 million in Q1 2025.
• The 5-year median for Equity Average is $127.5 million (2023), against an average of $115.3 million.
• Peak annual rise in Equity Average reached 2282.57% in 2025, while the deepest fall reached 165.04% in 2025.
• A 5-year view of Equity Average shows it stood at $132.9 million in 2022, then slipped by 11.55% to $117.6 million in 2023, then slumped by 127.07% to -$31.8 million in 2024, then surged by 904.03% to $255.9 million in 2025, then advanced by 22.88% to $314.5 million in 2026.
• The last three Equity Average figures came in at $314.5 million (Q1 2026), $255.9 million (Q4 2025), and $190.5 million (Q3 2025), per Business Quant data.

Peer Comparison